
        <!DOCTYPE html>
        <html>
        <head>
            <title>Celldex Therapeutics Inc. (CLDX) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Celldex Therapeutics Inc. (CLDX)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">‚Üê Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">8</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">3</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">2</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.18</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8db8884ef4b123973e2bdcd1fc64244b329e93781cd593cab4d6eda2f009e70b" target="_blank" rel="noopener noreferrer">Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-24</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.92
                                </span>
                            </div>
                            <div class="article-summary">Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e6d822ff65c9c4e39bc3b867a552c9d7c44af0f53d47723c2b45cbe695442b1a" target="_blank" rel="noopener noreferrer">Celldex Therapeutics to Present at Upcoming Investor Conferences</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-04</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=dd7eb599a8a12e688dfbd2ca91b1bf59e1c0ec5a6a46169b2f61256122bbfc43" target="_blank" rel="noopener noreferrer">Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-03</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">HAMPTON - Celldex Therapeutics, Inc. announced today positive data on measurements of disease control and quality of life from the Company's Phase 2 barzolvolimab studies in patients with chronic......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=44682df135ffc71cf6449edadfea3ebe53fcff4c6b0fb0125c1634a47aa926c1" target="_blank" rel="noopener noreferrer">Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-03</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.71
                                </span>
                            </div>
                            <div class="article-summary">- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics,...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=286d6247b88700ae113506239f29e7934009eb1b4a90492c886393e153066386" target="_blank" rel="noopener noreferrer">Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-01</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    -0.18
                                </span>
                            </div>
                            <div class="article-summary">Celldex Therapeutics ( NASDAQ:CLDX ) Full Year 2024 Results Key Financial Results Net loss: US$157.9m (loss widened by......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c85d38bdf7cce71dcfd06abc56f4c7e1f2ccacae412fa07aaa3839702da485ad" target="_blank" rel="noopener noreferrer">Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-02-27</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentPhase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollme...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c7bb5f2ce66d5a841588e7507877e4cd22dc40a6d33c473dc93f6e8cc9f34512" target="_blank" rel="noopener noreferrer">Celldex: Q4 Earnings Snapshot</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-02-27</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.55
                                </span>
                            </div>
                            <div class="article-summary">On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 71 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Inves...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9e76116b60eacc3daf2ff02a57f1f2e50425e5217be044706f03a1cf7fe88eac" target="_blank" rel="noopener noreferrer">Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-02-27</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.39
                                </span>
                            </div>
                            <div class="article-summary">Celldex (CLDX) delivered earnings and revenue surprises of 5.33% and 24.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        